For that vote, Ravi Thadhani, M.D., of Mass General Brigham switched to "yes," arguing that some patients could benefit from the treatment and that he's "convinced" AstraZeneca and FibroGen are taking the safety concerns seriously. During the meeting, panelists on the FDA's Cardiovascular and Renal Drugs Advisory Committee discussed the drug's safety and efficacy profile in both dialysis and nondialysis patients plus enrollment criteria for the clinical research program, a potential post-marketing study and more. RELATED: AstraZeneca, FibroGen's roxadustat hit with tough safety questions in FDA review ahead of key expert meeting Much of the discussion centered on the med's safety and the data the companies submitted with their application.